| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| WASHINGTON, D.C. 20549 |
| FORM 8-K |
| Current Report |
| Pursuant to Section 13 or 15(d) of the |
| Securities Exchange Act of 1934 |
| May 28, 2012 |
| Date of Report (Date of Earliest Event Reported) |
| IntelGenx Technologies Corp. |
| (Exact Name of Registrant as Specified in its Charter) |
| Delaware | 000-31187 | 870299034 |
| (State or other jurisdiction of | (Commission File | (IRS Employer Identification |
| incorporation) | Number) | No.) |
| 6425 Abrams, Ville St- Laurent, Quebec, Canada | H4S 1X9 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant's telephone number, including area code: (514) 331-7440 | |
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ]Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 7.01 Regulation FD Disclosure - News Release
IntelGenx Achieves Positive Pivotal Study Results for Bioequivalent Anti-Migraine VersaFilm Formulation of Maxalt-MLT®
| Exhibit | Description | |
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INTELGENX TECHNOLOGIES CORP. | ||
| Dated: May 29, 2012 | By: /s/ Horst Zerbe | |
| ------------------- | ||
| Horst G.Zerbe | ||
| President and Chief | ||
| Executive Officer | ||